尊龙凯时·(中国)人生就是搏!
ABOUT US
NEWS
INVESTOR RELATIONS
簡
繁
EN
ABOUT US
NEWS
INVESTOR RELATIONS
簡
繁
EN
簡
繁
EN
COMPANY NEWS
Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance
2024.03.19
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024.03.18
Change of Address of Head Office and Principal Place of Business in Hong Kong
2024.01.03
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2020-08-18
Essex Bio-Technology Reports First Half 2020 Financial Results
2020-08-10
Essex Bio-Technology Enters into Global Out-licence Agreement with Kelun-Biotech
2020-04-30
Essex Bio-Technology Joins X-ZELL Seed+ Investment Round
2020-03-17
FY 2019 Profit-After-Tax Up 30.9% to HK$302.5 million,was up 36.5% in RMB denomination
2019-12-27
Preservative-free Single-dose rb-bFGF Eye Drops (Single-Dose Beifushu Eye Drops) Obtained Approval from NMPA for Commercialisation in China
2019-12-12
Essex Bio-Technology and Mitotech Announce First Patient First Visit in U.S. FDA Second Phase 3 Clinical Trial of SkQ1
2019-08-21
Admission of Product to the PRC National Drug List for Reimbursement, Beifuxin Newly Listed and the Other Three Products Remain on the List
2019-08-12
Essex Biotech's mid-2019 net profit increased by 31% year-on-year to HK$129 million
<
3
4
5
6
7
8
9
>
Essex-Bio Group
BIOTECH
HEALTHTECH
Links
Wuhan Adv.Dental Bio-Technology
UNO Medical Group
Antikor Biopharma
Mitotech S.A.
Henlius
Humacyte
Copyright © 2020 Essex Bio-Technology Limited All Rights Reserved.
Disclaimer
|
Privacy Policy
粵公網安備 44049102496184號粵ICP備09032349號-1
互聯網藥品信息服務資格證書編號:(粵)-非經營性-2024-0208
深圳網站建設 深圳聯雅
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
ACCEPT